AU2014228785B2 - Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction - Google Patents

Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction Download PDF

Info

Publication number
AU2014228785B2
AU2014228785B2 AU2014228785A AU2014228785A AU2014228785B2 AU 2014228785 B2 AU2014228785 B2 AU 2014228785B2 AU 2014228785 A AU2014228785 A AU 2014228785A AU 2014228785 A AU2014228785 A AU 2014228785A AU 2014228785 B2 AU2014228785 B2 AU 2014228785B2
Authority
AU
Australia
Prior art keywords
selenium
pct
subject
present application
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014228785A
Other languages
English (en)
Other versions
AU2014228785A1 (en
Inventor
Casey EGAN
Lewis Collen Jackson
Stefan Kwiatkowski
Zi-Jian LAN
Ronan Power
Rijin XIAO
Alexander YIANNIKOURIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Corp filed Critical Alltech Corp
Publication of AU2014228785A1 publication Critical patent/AU2014228785A1/en
Application granted granted Critical
Publication of AU2014228785B2 publication Critical patent/AU2014228785B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014228785A 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction Active AU2014228785B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
US61/788,133 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Publications (2)

Publication Number Publication Date
AU2014228785A1 AU2014228785A1 (en) 2015-09-24
AU2014228785B2 true AU2014228785B2 (en) 2018-01-25

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014228785A Active AU2014228785B2 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Country Status (15)

Country Link
US (1) US9833486B2 (enExample)
EP (1) EP2968404A4 (enExample)
JP (1) JP6313418B2 (enExample)
KR (1) KR102245702B1 (enExample)
CN (3) CN114533753A (enExample)
AU (1) AU2014228785B2 (enExample)
BR (1) BR112015022514A2 (enExample)
CA (1) CA2903845C (enExample)
CL (1) CL2015002677A1 (enExample)
HK (1) HK1216506A1 (enExample)
MX (1) MX359626B (enExample)
RU (1) RU2663127C2 (enExample)
SG (2) SG11201507061XA (enExample)
WO (1) WO2014144776A1 (enExample)
ZA (1) ZA201506759B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022936A2 (pt) 2013-03-14 2017-07-18 J Schentag Jerome vesículas de colestossoma para a incorporação de moléculas em quilomícrons
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
AU2019261476B2 (en) * 2018-04-25 2021-11-18 Oncocross Co.,Ltd. Composition for preventing and treating muscular disease
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
KR20230029674A (ko) * 2020-06-29 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 생물반응기로부터의 샘플을 분석하기 위한 자동화 시스템 및 방법
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013951A2 (en) * 2003-08-11 2005-02-17 Pomeranian Academy Of Medicine Pharmaceutical compositions for preventing breast and ovarian cancer
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1774972A1 (en) * 2005-10-14 2007-04-18 Alltech, Inc. Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
EP1643865A1 (en) * 2003-06-04 2006-04-12 Willem Jacob Serfontein Nutritional compositions and use thereof
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US8846111B2 (en) * 2007-05-18 2014-09-30 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
CN102056499B (zh) * 2007-10-16 2014-12-31 阿克特基因组学有限公司 用于调节脂质代谢的组合物
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
RU2012120785A (ru) * 2009-10-22 2013-11-27 ПРОПАНК ПиТиУай ЛТД Фармацевтические композиции
JP5896421B2 (ja) * 2010-04-22 2016-03-30 国立大学法人京都大学 多能性幹細胞から骨格筋または骨格筋前駆細胞への分化誘導法
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013951A2 (en) * 2003-08-11 2005-02-17 Pomeranian Academy Of Medicine Pharmaceutical compositions for preventing breast and ovarian cancer
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1774972A1 (en) * 2005-10-14 2007-04-18 Alltech, Inc. Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PINTO ET AL., "Supranutritional selenium induces alterations in molecular targets related to energy metabolism in skeletal muscle and visceral adipose tissue of pigs.", J INORG BIOCHEM., (2012-04-30), vol. 114, pages 47 - 54 *
SNYDER, JESSICA LYNN READ., "Genomic Analysis of the Influence of Selenium Sources in Broiler Chickens Challenged with an Enteric Avian Reovirus.", MASTERS THESIS., (2009), pages 1 - 243 *

Also Published As

Publication number Publication date
CA2903845A1 (en) 2014-09-18
JP6313418B2 (ja) 2018-04-18
SG11201507061XA (en) 2015-10-29
JP2016516058A (ja) 2016-06-02
KR20150132374A (ko) 2015-11-25
NZ711842A (en) 2021-04-30
US20160113977A1 (en) 2016-04-28
RU2015139742A (ru) 2017-04-21
AU2014228785A1 (en) 2015-09-24
US9833486B2 (en) 2017-12-05
CN114984038A (zh) 2022-09-02
MX2015013275A (es) 2015-12-11
CL2015002677A1 (es) 2016-12-09
CA2903845C (en) 2022-08-23
CN105377271A (zh) 2016-03-02
EP2968404A1 (en) 2016-01-20
HK1216506A1 (zh) 2016-11-18
KR102245702B1 (ko) 2021-04-28
MX359626B (es) 2018-10-01
ZA201506759B (en) 2017-03-29
CN114533753A (zh) 2022-05-27
EP2968404A4 (en) 2017-01-04
BR112015022514A2 (pt) 2017-07-18
SG10202101918RA (en) 2021-03-30
WO2014144776A1 (en) 2014-09-18
RU2663127C2 (ru) 2018-08-01

Similar Documents

Publication Publication Date Title
AU2014228785B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Liu et al. The physiological metabolite α-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress
Koklesova et al. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person
Li et al. Syringaresinol protects against type 1 diabetic cardiomyopathy by alleviating inflammation responses, cardiac fibrosis, and oxidative stress
Dong et al. Juglanin suppresses fibrosis and inflammation response caused by LPS in acute lung injury
AU2010247734B2 (en) Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
Chen et al. Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis
Chong et al. Neurogenesis-dependent antidepressant-like activity of Hericium erinaceus in an animal model of depression
Li et al. Bailcalin Protects Against Diabetic Cardiomyopathy Through Keap1/Nrf2/AMPK‐Mediated Antioxidative and Lipid‐Lowering Effects
Wang et al. Nitration-mediated deficiency of cystathionine β-synthase activity accelerates the progression of hyperhomocysteinemia
Zhang et al. Effects and mechanisms of Polygonati Rhizoma polysaccharide on potassium oxonate and hypoxanthine-induced hyperuricemia in mice
Gong et al. Integration of transcriptomics and metabonomics revealed the protective effects of hemp seed oil against methionine–choline-deficient diet-induced non-alcoholic steatohepatitis in mice
Ru et al. Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects
Sun et al. Functional roles of folic acid in alleviating dexamethasone‐induced fatty liver syndrome in laying hens
Chen et al. Multi-omics strategy reveals that Cordyceps sinensis ameliorates sepsis-associated acute kidney injury via reprogramming of mitochondrial energy metabolism and macrophage polarization
Xu et al. Black rice phenolics alleviate T2DM through comprehensive regulation of oxidative stress, metabolic pathways and gut microbiota
Xu et al. Metformin-mediated intestinal AMPK activation ameliorates PCOS through gut microbiota modulation and metabolic pathways
Ren et al. Astaxanthin slows down skeletal muscle atrophy in H22 tumor-bearing mice during sorafenib treatment by modulating the gut microbiota
Gu et al. β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice
Gu et al. Phlorizin mitigates high glucose-induced metabolic disorders through the IIS pathway in Caenorhabditis elegans
NZ711842B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
JP2017515830A (ja) ７−ヒドロキシマタイレシノールを含む組成物
US20230000888A1 (en) Nad-precursors and dietary restriction for treating age related medical conditions
Zhang et al. Malus hupehensis leaves: a functional beverage for alleviating hepatic inflammation and modulating gut microbiota in diabetic mice
Wang et al. Integrated proteomics and metabolomics to clarify the essential beneficial mechanisms of L-theanine in alleviating ISO-induced cardiac damage in mice

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)